Remove Blogging Remove Pricing Remove Study Remove Thousand Oaks
article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts.